Tecentriq is an immunotherapy drug that stimulates the body’s immune system to detect and attack cancer cells.
Patients with or without a tumor protein called PD-L1, which typically makes people more receptive to immunotherapy treatments, can use Tecentriq, according to Reuters.
The FDA based the approval on the results of a recent late-stage clinical trial showing patients taking Tecentriq lived, on average, 4.2 months longer than those treated with chemotherapy.
More articles on supply chain:
Tenn. high school opens medical device machinery lab
Sen. Blumenthal urges DOJ to reject Mylan settlement
TPC names ROi preferred supply chain partner: 3 things to know
